martes, 17 de noviembre de 2026

FDA Green-Lights New Breast Cancer Drug From Roche

FDA Green-Lights New Breast Cancer Drug From Roche The approval of Wilserdly, also known as giredestrant, is specifically for patients with HR-positive, HER2-negative advanced breast cancer that has picked up a mutation in the ESR1 gene, a sign that the tumor is developing resistance to standard treatments, Stat reported. Also in pharma industry news: Alzheimer's treatments, weight loss drugs, and more. https://kffhealthnews.org/morning-breakout/pub-health-111726/

No hay comentarios: